Evidence map›Paper›PMID 36615769›Full record

ArticleNutrients2022

Extensively Hydrolyzed Hypoallergenic Infant Formula with Retained T Cell Reactivity.

Raphaela Freidl, Victoria Garib, Birgit Linhart, Elisabeth M Haberl, Isabelle Mader, Zsolt Szépfalusi, Klara Schmidthaler, Nikos Douladiris, Alexander Pampura, Evgeniy Varlamov and 10 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nutrients, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Nutrients · 2023
    Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 5 institutions in 3 countries.

Raphaela FreidlCenter for Pathophysiology, Infectiology and Immunology, Institute of Pathophysiology and Allergy Research, Medical University of Vienna, A-1090 Vienna, Austria.
Victoria GaribCenter for Pathophysiology, Infectiology and Immunology, Institute of Pathophysiology and Allergy Research, Medical University of Vienna, A-1090 Vienna, Austria.
Birgit LinhartCenter for Pathophysiology, Infectiology and Immunology, Institute of Pathophysiology and Allergy Research, Medical University of Vienna, A-1090 Vienna, Austria.
Elisabeth M HaberlHiPP GmbH & Co. Vertrieb KG, 85276 Pfaffenhofen, Germany.
Isabelle MaderHiPP GmbH & Co. Vertrieb KG, 85276 Pfaffenhofen, Germany.
Zsolt SzépfalusiDepartment of Pediatrics and Adolescent Medicine, Division of Pediatric Pulmonology, Allergy and Endocrinology, Comprehensive Center of Pediatrics, Medical University Vienna, A-1090 Vienna, Austria.
Klara SchmidthalerDepartment of Pediatrics and Adolescent Medicine, Division of Pediatric Pulmonology, Allergy and Endocrinology, Comprehensive Center of Pediatrics, Medical University Vienna, A-1090 Vienna, Austria.
Nikos DouladirisAllergy Department, 2nd Pediatric Clinic, National & Kapodistrian University of Athens, 11527 Athens, Greece.
Alexander PampuraDepartment of Allergology and Clinical Immunology, Research and Clinical Institute for Pediatrics Named after Yuri Veltischev at the Pirogov Russian National Research Medical University of the Russian Ministry of Health, 117997 Moscow, Russia.
Evgeniy VarlamovDepartment of Allergology and Clinical Immunology, Research and Clinical Institute for Pediatrics Named after Yuri Veltischev at the Pirogov Russian National Research Medical University of the Russian Ministry of Health, 117997 Moscow, Russia.
Tatiana LepeshkovaDepartment of Faculty Therapy, Endocrinology, Allergology and Immunology, Ural State Medical University, 620014 Ekaterinburg, Russia.
Evgeny BeltyukovDepartment of Faculty Therapy, Endocrinology, Allergology and Immunology, Ural State Medical University, 620014 Ekaterinburg, Russia.
Veronika NaumovaDepartment of Faculty Therapy, Endocrinology, Allergology and Immunology, Ural State Medical University, 620014 Ekaterinburg, Russia.ORCID 0000-0002-3028-2657
Styliani TakaAllergy Department, 2nd Pediatric Clinic, National & Kapodistrian University of Athens, 11527 Athens, Greece.ORCID 0000-0001-7607-8005
Dina NosovaAllergy Department, UNIMED Laboratories, 119049 Moscow, Russia.
Olga GuliashkoAllergy Department, UNIMED Laboratories, 119049 Moscow, Russia.
Michael KundiDepartment for Environmental Heath, Center for Public Health, Medical University of Vienna, A-1090 Vienna, Austria.ORCID 0000-0002-2707-3213
Alina KiyamovaInternational Center of Molecular Allergology, Ministry of Innovation Development, Tashkent 100174, Uzbekistan.
Stefani KatsamakiInternational Center of Molecular Allergology, Ministry of Innovation Development, Tashkent 100174, Uzbekistan.
Rudolf ValentaCenter for Pathophysiology, Infectiology and Immunology, Institute of Pathophysiology and Allergy Research, Medical University of Vienna, A-1090 Vienna, Austria.
Medical University of Vienna · ATUral State Medical University · RUNational and Kapodistrian University of Athens · GRPirogov Russian National Research Medical University · RUSechenov University · RU

Funding

HiPP GmbH & Co. Vertrieb KG, Pfaffenhofen, Germany HIPP ATU57469858
6 · The paper itself

Abstract

backgroundImmunoglobulin E (IgE)-mediated cow's milk allergy (CMA) can be life-threatening and affects up to 3% of children. Hypoallergenic infant formulas based on hydrolyzed cow's milk protein are increasingly considered for therapy and prevention of cow's milk allergy. The aim of this study was to investigate the allergenic activity and ability to induce T cell and cytokine responses of an infant formula based on extensively hydrolyzed cow's milk protein (whey) (eHF, extensively hydrolyzed formula) supplemented with Galactooligosaccharides (GOS) and

methodseHF and standard protein formula based on intact cow's milk proteins (iPF) with or without Galactooligosaccharide (GOS) and

resultsAn eHF supplemented with GOS and LF exhibiting almost no IgE reactivity and allergenic activity was identified. This eHF induced significantly lower inflammatory cytokine secretion as compared to an intact protein-based infant formula but retained T cell reactivity.

conclusionsDue to strongly reduced allergenic activity and induction of inflammatory cytokine secretion but retained T cell reactivity, the identified eHF may be used for treatment and prevention of CMA by induction of specific T cell tolerance.

Indexed as

Infant FormulaMilk HypersensitivityAllergensAnimalsCattleCytokinesFemaleLeukocytes, MononuclearMilk ProteinsT-LymphocytesAllergensCytokinesMilk Proteinsallergenallergycow’s milk allergyhypoallergenic infant formula

Identifiers

PMID36615769
PMCPMC9824366
OpenAlexW4313244813

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.